Innovation Pharmaceuticals Inc (IPIX)

[Michel]

lowest closing of the year on January 13 0.1755$, yesterday 0.1762$

January 14 and 15 increased from 0.14$ to 0.23$ due to the FDA FAST TRACK DESIGNATION,
Since then a few good press releases to get us to 0.50$ and back to 0.17$, as if nothing had happened


April 28, 2021
INNOVATION PHARMA SURPASSES 50 PERCENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19

April 14, 2021
INNOVATION PHARMA’S BROAD SPECTRUM ANTIVIRAL DRUG CANDIDATE BRILACIDIN HIGHLIGHTED IN BIODEFENSE AND INFECTIOUS DISEASES COVID-19 PRESENTATION

April 7, 2021
INNOVATION PHARMA ANNOUNCES BRILACIDIN ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY FOR VIROLOGY’S ANNUAL MEETING

April 5, 2021
INNOVATION PHARMA COMPLETES INTERIM SAFETY DATA REVIEW—DMC APPROVES INCREASED DOSING FREQUENCY IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS

March 10, 2021
INNOVATION PHARMA’S COVID-19 DRUG CANDIDATE BRILACIDIN RANKED IN TOP THREE PERCENT OF COMPOUNDS PREDICTED TO BE MOST EFFECTIVE AGAINST SARS-COV-2

March 5, 2021
RECRUITMENT AND ENROLLMENT UNDERWAY AT EIGHT SITES FOR INNOVATION PHARMA’S PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19

March 2, 2021
INNOVATION PHARMACEUTICALS ANNOUNCES PUBLICATION OF PEER-REVIEWED SCIENTIFIC ARTICLE IN THE JOURNAL VIRUSES ON THE ANTI-SARS-COV-2 PROPERTIES OF BRILACIDIN

February 26, 2021
INNOVATION PHARMA PROVIDES STUDY DETAILS FOR ONGOING PHASE 2 CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS

January 29, 2021
INNOVATION PHARMACEUTICALS’ PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR TREATING COVID-19 SCHEDULED TO BEGIN NEXT WEEK

January 14, 2021
INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR THE TREATMENT OF COVID-19 RECEIVES FDA FAST TRACK DESIGNATION